Ibtessam Hussein

Prof. Ibtessam Hussein

orcid

Research Focus & Metrics

Academic Career Length

19Years (2008-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
20 July 2016 in BMC Genomics
Verified
Journal Article
Open access
JSJerry W. Shay
Jerry W. Shay
NHNoriko Homma
Noriko Homma
RZRuyun Zhou
Ruyun Zhou
MNMuhammad Imran Naseer
Muhammad Imran Naseer
ACAdeel Chaudhary
Adeel Chaudhary
SBSaleh Binsaleh
Saleh Binsaleh
O1 Regulation of genes by telomere length over long distances

14 February 2022 in Evidence-Based Complementary and Alternative Medicine
Verified
Journal Article
Open access
PDF file
AAAdel M. Abuzenadah
Adel M. Abuzenadah
FAFatin Al-Sayes
Fatin Al-Sayes
SASyed Sahajada Mahafujul Alam
Syed Sahajada Mahafujul Alam
MHMehboob Hoque
Mehboob Hoque
SKSajjad Karim
Sajjad Karim
STShams Tabrez
Shams Tabrez
Angiogenesis plays a critical role in tumorigenesis as it provides the necessary blood supply to the newly grown solid tumor. It helps maintain the tumor microenvironment, promotes tumor development, progression, and metastasis. The vascular epithelial growth factor (VEGF), interacting with the tyrosine kinase receptor VEGFR-2 on endothelial cells, exerts its proangiogenic activity. Hence, targeting the VEGFR-2 signaling is considered a promising strategy to inhibit angiogenesis and thus cancer treatment. This study aims to identify the bioactive compounds derived from the medicinal herb Rauwolfia serpentina that effectively binds with VEGFR-2. The bioactive compounds of R. serpentina were first screened for their physicochemical properties using the DataWarrior program (version 5.5.0). Finally, 17 compounds that obeyed Lipinskis rule of five and showed good drug-likeness were selected for molecular docking studies. Molecular docking results showed that the ligands ajmalicidine, 1, 2-dihydrovomilenine, rauwolscine, yohimbine, ajmaline, and papaverine interact strongly with the target VEGFR-2 receptor. Hydrogen bonds and hydrophobic interactions stabilized the interactions of these compounds with VEGFR-2. These compounds showed favourable drug-like properties and possess no significant toxicity. Therefore, the findings of this study indicate that the compounds derived from R. serpentina can be considered for the development of antiangiogenic drug candidates by targeting VEGFR-2.

28 July 2011 in Hemoglobin
Verified
Journal Article
Closed access
PDF file
AAAdel M. Abuzenadah
Adel M. Abuzenadah
IHIbtessam Hussein
Ibtessam Hussein
GDGhazi A. Damanhouri
Ghazi A. Damanhouri
FAFaten M. A-Sayes
Faten M. A-Sayes
MGMamdouh A. Gari
Mamdouh A. Gari
MAMohammad H. Al-Qahtani
Mohammad H. Al-Qahtani
This study aimed at the identification of the spectrum of mutations in patients with β-thalassemia (β-thal) in the western province of Saudi Arabia. Screening for the mutations was done using the polymerase chain reaction-amplification refractory mutation system (PCR-ARMS) technique to test for 12 mutations, and direct automated DNA sequencing for the unknown samples. The study included 172 patients; of these 15 patients had sickle cell anemia and one Hb S [β6(A3)Glu→Val, GAG>GTG]/β-thal. A total of 23 mutations were identified to cause the disease in the western area. Seven common mutations were responsible for the β-thal alleles in 78% of patients and could be detected by the ARMS technique: IVS-II-1 (G>A), IVS-I-110 (G>A), IVS-I-5 (G>C), codon 39 (C>T), codon 26 (G>A) [Hb E or β26(B8)Glu→Lys, GAG>AAG], frameshift codons (FSC) 8/9 (+G), and IVS-I-1 (G>A). DNA sequencing of uncharacterized alleles detected eight less common mutations: FSC 41/42 (–TCTT), IVS-I 25 bp deletion, codon 37 (G>A), FSC 44 (–C), Cap site +1 (A>C), IVS-I-6 (T>C), FSC 5 (–CT) and IVS-I-1 (G>T), and eight rare mutations: −87 (C>G), initiation codon −1 (T>G), codon 15 (G>A), FSC 16 (–C), FSC 20/21 (+G), codon 27 (G>A), IVS-I-130 (G>C) and IVS-II-837 (A>C). Four alleles were normal by DNA sequencing. Genetic heterogeneity was observed in this study, 10 mutations were of Asian or Asian/Indian origin, two were Kurdish, one Chinese, one Turkish, one Saudi, and the remainder were of Mediterranean origin. The presence of a large population of immigrants in the western province is responsible for the great heterogeneity at the molecular level, and for the difference observed in the frequencies of mutations from those reported in the eastern province of Saudi Arabia. Screening for β-thal mutations using PCR-ARMS for the seven most frequent mutations in the Saudi population followed by DNA sequencing of the unknown alleles could be useful for the implementation of a strategy for carrier detection and preimplantation genetic diagnosis in high risk families.

15 January 2015 in BMC Genomics
Verified
Journal Article
Open access
PDF file
AMAdnan Merdad
Adnan Merdad
MGMamdooh A Gari
Mamdooh A Gari
SHShireen Hussein
Shireen Hussein
SAShadi Al-Khayat
Shadi Al-Khayat
HTHana Tashkandi
Hana Tashkandi
ADAshraf Dallol
Ashraf Dallol
The contribution of genetic factors to the development of breast cancer in the admixed and consanguineous population of the western region of Saudi Arabia is thought to be significant as the disease is early onset. The current protocols of continuous clinical follow-up of relatives of such patients are costly and cause a burden on the usually over-stretched medical resources. Discovering the significant contribution of BRCA1/2 mutations to breast cancer susceptibility allowed for the design of genetic tests that allows the medical practitioner to focus the care for those who need it most. However, BRCA1/2 mutations do not account for all breast cancer susceptibility genes and there are other genetic factors, known and unknown that may play a role in the development of such disease. The advent of whole-exome sequencing is offering a unique opportunity to identify the breast cancer susceptibility genes in each family of sufferers. The polymorphisms/mutations identified will then allow for personalizing the genetic screening tests accordingly. To this end, we have performed whole-exome sequencing of seven breast cancer patients with positive family history of the disease using the Agilent SureSelect™ Whole-Exome Enrichment kit and sequencing on the SOLiD™ platform.

14 March 2018 in Pediatric Cardiology
Verified
Journal Article
Closed access
PDF file
IHIbtessam Hussein
Ibtessam Hussein
RBRima S. Bader
Rima S. Bader
ACAdeel G. Chaudhary
Adeel G. Chaudhary
RBRanda Bassiouni
Randa Bassiouni
MAMaha Alquaiti
Maha Alquaiti
MQMohammad H. Al Qahtani
Mohammad H. Al Qahtani

23 March 2022 in Evidence-Based Complementary and Alternative Medicine
Verified
Journal Article
Open access
PDF file
AAAdel M. Abuzenadah
Adel M. Abuzenadah
FAFatin Al-Sayes
Fatin Al-Sayes
SASyed Sahajada Mahafujul Alam
Syed Sahajada Mahafujul Alam
MHMehboob Hoque
Mehboob Hoque
SKSajjad Karim
Sajjad Karim
STShams Tabrez
Shams Tabrez
Poly (ADP-ribose) polymerase-1 (PARP-1) has been recognized as a prospective target for the development of novel cancer therapeutics. Several PARP-1 inhibitors are currently being considered for anticancer drug development and clinical investigation. Lately, natural compounds seem to be excellent alternative drug candidates for cancer treatment. Rauwolfia serpentina is a medicinal plant traditionally used in Indian subcontinents to treat various diseases. This study has been designed to identify the bioactive compounds derived from R. serpentina for possible binding and inhibition of PARP-1 using the molecular docking approach. Thirteen compounds were found to interact with the target with a binding affinity greater than the value of 9.0kcal/mol. After screening the physicochemical properties, only 5 ligands (ajmalicine, yohimbine, isorauhimbine, rauwolscine, and 1,2-dihydrovomilenine) were found to obey all the parameters of Lipinskis rule of five, showed maximum drug-likeness, and possess no significant toxicity. These ligands displayed strong interactions with target PARP-1 via several hydrogen bonds and hydrophobic interactions. Therefore, these identified compounds derived from R. serpentina can be considered for drug development against cancer-targeting PARP-1.